Synthetic Fluorinated l-Fucose Analogs Inhibit Proliferation of Cancer Cells and Primary Endothelial Cells.

Abstract

Fucosylation is one of the most prevalent modifications on N- and O-glycans of glycoproteins, and it plays an important role in various cellular processes and diseases. Small molecule inhibitors of fucosylation have shown promise as therapeutic agents for sickle cell disease, arthritis, and cancer. We describe here the design and synthesis of a panel of fluorinated l-fucose analogs bearing fluorine atoms at the C2 and/or C6 positions of l-fucose as metabolic fucosylation inhibitors. Preliminary study of their effects on cell proliferation revealed that the 6,6-difluoro-l-fucose (3) and 6,6,6-trifluoro-l-fucose (6) showed significant inhibitory activity against proliferation of human colon cancer cells and human umbilical vein endothelial cells. In contrast, the previously reported 2-deoxy-2-fluoro-l-fucose (1) had no apparent effects on proliferations of all the cell lines tested. To understand the mechanism of cell proliferation inhibition by the fluorinated l-fucose analogs, we performed chemoenzymatic synthesis of the corresponding GDP-fluorinated l-fucose analogs and tested their inhibitory activities against the mammalian α1,6-fucosyltransferase (FUT8). Interestingly, the corresponding GDP derivatives of 6,6-difluoro-l-fucose (3) and 6,6,6-trifluoro-l-fucose (6), which are the stronger proliferation inhibitors, showed much weaker inhibitory activity against FUT8 than that of the 2-deoxy-2-fluoro-l-fucose (1). These results suggest that FUT8 is not the major target of the 6-fluorinated fucose analogs (3 and 6). Instead, other factors, such as the key enzymes involved in the de novo GDP-fucose biosynthetic pathway and/or other fucosyltransferases involved in the biosynthesis of tumor-associated glyco-epitopes are most likely the targets of the fluorinated l-fucose analogs to achieve cell proliferation inhibition. To our knowledge, this is the first comparative study of various fluorinated l-fucose analogs for suppressing the proliferation of human cancer and primary endothelial cells required for angiogenesis.

• Authors: Yuanwei Dai, Ruth Hartke, Chao Li, Qiang Yang, Jun O Liu, Lai-Xi Wang
• Journal: ACS chemical biology (ACS Chem Biol) Vol. 15 Issue 10 Pg. 2662-2672 (10 16 2020) ISSN: 1554-8937 [Electronic] United States
• PMID: 32930566 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Antineoplastic Agents
• Enzyme Inhibitors
• Fucose
• Fucosyltransferases
• Glycoprotein 6-alpha-L-fucosyltransferase

Topics

• Antineoplastic Agents (chemical synthesis, pharmacology)
• Carbohydrate Sequence
• Cell Line, Tumor
• Cell Proliferation (drug effects)
• Drug Design
• Drug Evaluation, Preclinical
• Drug Screening Assays, Antitumor
• Endothelial Cells (drug effects)
• Enzyme Assays
• Enzyme Inhibitors (chemical synthesis, pharmacology)
• Fucose (analogs & derivatives, pharmacology)
• Fucosyltransferases (antagonists & inhibitors)
• Human Umbilical Vein Endothelial Cells
• Humans
• Molecular Structure